## Clarithromycin - Digoxin DDI

**Gurley 2006** Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P, Yates CR, Song PF, Hubbard MA, Tong Y, Cheboyina S Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos. 2006 Jan;34(1):69-74. doi: 10.1124/dmd.105.006312. Epub 2005   

**Gurley 2007** Gurley BJ, Swain A, Barone GW, Williams DK, Breen P, Yates CR, Stuart LB, Hubbard MA, Tong Y, Cheboyina S Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos. 2007 Feb;35(2):240-5. doi: 10.1124/dmd.106.012708. Epub 2006   

**Gurley 2008b** Gurley BJ, Swain A, Williams DK, Barone G, Battu SK Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res. 2008 Jul;52(7):772-9. doi: 10.1002/mnfr.200700081.  

**Kurata 2002** Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, Ohdo S, Ohtani H, Sawada Y, Higuchi S, Otsubo K Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther. 2002 Aug;72(2):209-19. doi: 10.1067/mcp.2002.126177.  

**Rengelshausen 2003** Rengelshausen J, Goggelmann C, Burhenne J, Riedel KD, Ludwig J, Weiss J, Mikus G, Walter-Sack I, Haefeli WE Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. Br J Clin Pharmacol. 2003 Jul;56(1):32-8. doi: 10.1046/j.1365-2125.2003.01824.x.  

**Tsutsumi 2002** Tsutsumi K, Kotegawa T, Kuranari M, Otani Y, Morimoto T, Matsuki S, Nakano S The effect of erythromycin and clarithromycin on the pharmacokinetics of intravenous digoxin in healthy volunteers. J Clin Pharmacol. 2002 Oct;42(10):1159-64. doi: 10.1177/009127002401382641.  

## Erythromycin-Digoxin-DDI

**Tsutsumi 2002** Tsutsumi K, Kotegawa T, Kuranari M, Otani Y, Morimoto T, Matsuki S, Nakano S. The effect of erythromycin and clarithromycin on the pharmacokinetics of intravenous digoxin in healthy volunteers. *J Clin Pharmacol*. 2002 Oct;42(10):1159-64. doi: 10.1177/009127002401382641. PMID: 12362931.

## Itraconazole-Digoxin-DDI

**Jalava 1997** Jalava KM, Partanen J, Neuvonen PJ. Itraconazole decreases renal clearance of digoxin. Ther Drug Monit. 1997 Dec;19(6):609-13. doi: 10.1097/00007691-199712000-00001. PMID: 9421099.

**Partanen 1995** Partanen J, Jalava KM, Neuvonen PJ. Itraconazole increases serum digoxin concentration. Pharmacol Toxicol. 1996 Nov;79(5):274-6. doi: 10.1111/j.1600-0773.1996.tb00273.x. PMID: 8936563.

## Rifampicin-Digoxin-DDI

**Drescher 2003** Drescher S, Glaeser H, Mürdter T, Hitzl M, Eichelbaum M, Fromm MF. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther. 2003 Mar;73(3):223-31. doi: 10.1067/mcp.2003.27. PMID: 12621387.

**Gurley 2006** Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P, Yates CR, Song PF, Hubbard MA, Tong Y, Cheboyina S. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos. 2006 Jan;34(1):69-74. doi: 10.1124/dmd.105.006312. Epub 2005 Oct 12. PMID: 16221754; PMCID: PMC1865121.

**Gurley 2007** Gurley BJ, Swain A, Barone GW, Williams DK, Breen P, Yates CR, Stuart LB, Hubbard MA, Tong Y, Cheboyina S. Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos. 2007 Feb;35(2):240-5. doi: 10.1124/dmd.106.012708. Epub 2006 Nov 1. PMID: 17079360; PMCID: PMC1868501.

**Gurley 2008b** Gurley BJ, Swain A, Williams DK, Barone G, Battu SK. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res. 2008 Jul;52(7):772-9. doi: 10.1002/mnfr.200700081. PMID: 18214850; PMCID: PMC2562898.

**Greiner 1999** Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest. 1999 Jul;104(2):147-53. doi: 10.1172/JCI6663. Erratum in: J Clin Invest 2002 Aug;110(4):571. PMID: 10411543; PMCID: PMC408477.

**Kirby 2012** Kirby BJ, Collier AC, Kharasch ED, Whittington D, Thummel KE, Unadkat JD. Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion. Drug Metab Dispos. 2012 Mar;40(3):610-6. doi: 10.1124/dmd.111.042705. Epub 2011 Dec 21. PMID: 22190694; PMCID: PMC3286266.

**Larsen 2007** Larsen UL, Hyldahl Olesen L, Guldborg Nyvold C, Eriksen J, Jakobsen P, Østergaard M, Autrup H, Andersen V. Human intestinal P-glycoprotein activity estimated by the model substrate digoxin. Scand J Clin Lab Invest. 2007;67(2):123-34. doi: 10.1080/00365510600986084. PMID: 17365992.

**Reitmann 2011** Reitman ML, Chu X, Cai X, Yabut J, Venkatasubramanian R, Zajic S, Stone JA, Ding Y, Witter R, Gibson C, Roupe K, Evers R, Wagner JA, Stoch A. Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Ther. 2011 Feb;89(2):234-42. doi: 10.1038/clpt.2010.271. Epub 2010 Dec 29. PMID: 21191377.

**Wiebe 2020** Wiebe ST, Giessmann T, Hohl K, Schmidt-Gerets S, Hauel E, Jambrecina A, Bader K, Ishiguro N, Taub ME, Sharma A, Ebner T, Mikus G, Fromm MF, Müller F, Stopfer P. Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine. Clin Pharmacokinet. 2020 Dec;59(12):1627-1639. doi: 10.1007/s40262-020-00907-w. PMID: 32504272; PMCID: PMC7716890.

## Verapamil - Digoxin DDI

**Belz 1981** Belz GG, Aust PE, Munkes R. Digoxin plasma concentrations and nifedipine. Lancet. 1981 Apr 11;1(8224):844-5. doi: 10.1016/s0140-6736(81)92727-6. PMID: 6111709.

**Belz 1983** Belz GG, Doering W, Munkes R, Matthews J. Interaction between digoxin and calcium antagonists and antiarrhythmic drugs. Clin Pharmacol Ther. 1983 Apr;33(4):410-7. doi: 10.1038/clpt.1983.55. PMID: 6831819.

**Doering 1983** Doering W. Effect of coadministration of verapamil and quinidine on serum digoxin concentration. Eur J Clin Pharmacol. 1983;25(4):517-21. doi: 10.1007/BF00542121. PMID: 6653647.

**Johnson 1987** Johnson BF, Wilson J, Marwaha R, Hoch K, Johnson J. The comparative effects of verapamil and a new dihydropyridine calcium channel blocker on digoxin pharmacokinetics. Clin Pharmacol Ther. 1987 Jul;42(1):66-71. doi: 10.1038/clpt.1987.109. PMID: 2954736.

**Klein 1982** Klein HO, Lang R, Weiss E, Di Segni E, Libhaber C, Guerrero J, Kaplinsky E. The influence of verapamil on serum digoxin concentration. Circulation. 1982 May;65(5):998-1003. doi: 10.1161/01.cir.65.5.998. PMID: 7074765.

**Pedersen 1981** Pedersen KE, Dorph-Pedersen A, Hvidt S, Klitgaard NA, Nielsen-Kudsk F. Digoxin-verapamil interaction. Clin Pharmacol Ther. 1981 Sep;30(3):311-6. doi: 10.1038/clpt.1981.165. PMID: 7273594.

**Pedersen 1982** Pedersen KE, Dorph-Pedersen A, Hvidt S, Klitgaard NA, Pedersen KK. The long-term effect of verapamil on plasma digoxin concentration and renal digoxin clearance in healthy subjects. Eur J Clin Pharmacol. 1982;22(2):123-7. doi: 10.1007/BF00542456. PMID: 7094982.

**Pedersen 1983** Pedersen KE, Thayssen P, Klitgaard NA, Christiansen BD, Nielsen-Kudsk F. Influence of verapamil on the inotropism and pharmacokinetics of digoxin. Eur J Clin Pharmacol. 1983;25(2):199-206. doi: 10.1007/BF00543791. PMID: 6628501.

**Rodin 1988** Rodin SM, Johnson BF, Wilson J, Ritchie P, Johnson J. Comparative effects of verapamil and isradipine on steady-state digoxin kinetics. Clin Pharmacol Ther. 1988 Jun;43(6):668-72. doi: 10.1038/clpt.1988.93. PMID: 2967742.

**Schwartz 1982** Schwartz JB, Keefe D, Kates RE, Kirsten E, Harrison DC. Acute and chronic pharmacodynamic interaction of verapamil and digoxin in atrial fibrillation. Circulation. 1982 Jun;65(6):1163-70. doi: 10.1161/01.cir.65.6.1163. PMID: 7074776.

**Wiebe 2020** Wiebe ST, Giessmann T, Hohl K, Schmidt-Gerets S, Hauel E, Jambrecina A, Bader K, Ishiguro N, Taub ME, Sharma A, Ebner T, Mikus G, Fromm MF, Müller F, Stopfer P. Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine. Clin Pharmacokinet. 2020 Dec;59(12):1627-1639. doi: 10.1007/s40262-020-00907-w. PMID: 32504272; PMCID: PMC7716890.

